Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

Rhea-AI Summary

Puma Biotechnology (PBYI) will host a conference call on February 25, 2021, at 1:30 p.m. PST/4:30 p.m. EST to discuss its fourth quarter and full-year 2020 financial results. Investors can join by calling 1-877-709-8150 for domestic or 1-201-689-8354 for international access. A live webcast and presentation slides will be available on Puma's website. The company specializes in biopharmaceuticals focused on cancer care, known for its FDA-approved drug NERLYNX (neratinib), which treats specific types of breast cancer.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth quarter and full year 2020 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005729/en/

FAQ

When will Puma Biotechnology announce its Q4 and full-year 2020 financial results?

Puma Biotechnology will announce its Q4 and full-year 2020 financial results on February 25, 2021.

What is the ticker symbol for Puma Biotechnology?

The ticker symbol for Puma Biotechnology is PBYI.

How can I access the Puma Biotechnology conference call?

You can access the conference call by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international) and joining at least 10 minutes early.

What product is Puma Biotechnology known for?

Puma Biotechnology is known for its FDA-approved drug NERLYNX (neratinib), used for treating certain breast cancer patients.

Will there be a replay of the conference call?

Yes, a replay of the conference call will be available approximately one hour after its completion and archived on Puma's website for 90 days.